5 Questions: Stanford’s role in global effort to combat antibiotic resistance

A Stanford program has been designated as a collaborating center to help the World Health Organization combat the overuse and misuse of antibiotics.

Stanley Deresinski

The discovery of antibiotics like penicillin in the late 1920s revolutionized medicine, making surgeries safer and common bacterial infections less deadly. But the overuse and misuse of these lifesaving drugs has evolved into a global public health emergency: Many microorganisms naturally develop resistance to antibiotics over time, allowing for the emergence of “superbugs” that are no longer readily killed by available antibiotics.

After several years of working with the World Health Organization to promote the safe and optimal use of antibiotics worldwide, the Stanford Antimicrobial Safety and Sustainability program has been designated a WHO Collaborating Centre for Antimicrobial Resistance and Stewardship — the first designation of its kind.

Leading this effort are Stanford physician-scientists Stanley Deresinski, MD, clinical professor of infectious diseases, and Marisa Holubar, MD, clinical assistant professor of infectious diseases. Writer Julie Greicius reached out to them to learn more about the issue.

1. What makes antimicrobial resistance a global public health emergency? 

Marisa Holubar

Deresinski: Antibiotics are unlike other classes of drugs in that their very use guarantees their eventual obsolescence. As antibiotics lose their effectiveness, the treatment of infections becomes increasingly difficult and, in some cases, totally ineffective. As a consequence, there is concern that we are heading toward a post-antibiotic era — effectively reverting to a time before the availability of these “wonder drugs.” Without antibiotics, even a minor surgery could become life-threatening if ordinary antibiotics can't control infection. Recent predictions forecast that antimicrobial resistant infections could cause 10 million deaths globally each year by 2050. This demands immediate and coordinated action to avert disaster.  

2. What does it mean to be a World Health Organization Collaborating Centre, and what will be Stanford's role specifically? 

Holubar: WHO Collaborating Centre designations recognize at least two years of productive collaboration between the institution and WHO, and continued excellence in the field. Specifically, we will provide technical support and guidance to the WHO to strengthen the capacity of nations to implement antimicrobial stewardship programs in clinical care. We will also continue to develop and refine educational curricula and programs designed to enhance the competency of antimicrobial prescribers. 

3. What led to your collaboration with the WHO?

Deresinski: After starting our program at Stanford in 2012, we developed a massive open online course, Antimicrobial Stewardship: Improving Clinical Outcomes by Optimization of Antibiotic Practices, in which more than 30,000 students have enrolled. At the time, our colleagues at WHO in Copenhagen were looking for such freely available educational material and contacted us. We have been working with them ever since. Most recently, we developed a web-based course  for WHO, titled Antimicrobial Stewardship: A Competency Based Approach, which has enrolled over 21,000 since its release in January 2018. Other activities have included developing and implementing antimicrobial stewardship curricula, and participating in WHO missions in places such as Turkey, Armenia, Jordan and Uzbekistan.

4. What are the next steps?

Holubar: Optimizing the use of antimicrobials in resource-limited settings is complex and activities must be tailored to available resources. The complexity is illustrated by the fact that antibiotic overuse exists side by side with lack of access in some lower-income countries. There is no one-size-fits-all solution. For example, American stewardship programs typically are led by infectious disease physicians and pharmacists, but health care workers with this kind of training are uncommon in some countries. We are interested in developing resources, including educational materials, to help member states get started with their available resources and formally assess their progress.

5. What are the most important steps that physicians and patients can take to begin reducing antimicrobial resistance?

Deresinski: Clinicians should never consider antibiotic prescribing as routine. They should always take into account the balance between possible benefit and harm — not only to the individual patient, but to subsequent patients because of the effect of antibiotics on the microbiome and on the emergence of resistance.

Patients can learn the difference in symptoms between common viral infections, for which antibiotics provide no benefit, and more serious problems that may be due to bacterial infection. They should understand that antibiotics, although necessary in some circumstances, can also have harmful effects.



Stanford Medicine integrates research, medical education and health care at its three institutions - Stanford University School of Medicine, Stanford Health Care (formerly Stanford Hospital & Clinics), and Lucile Packard Children's Hospital Stanford. For more information, please visit the Office of Communication & Public Affairs site at http://mednews.stanford.edu.

Leading in Precision Health

Stanford Medicine is leading the biomedical revolution in precision health, defining and developing the next generation of care that is proactive, predictive and precise. 

A Legacy of Innovation

Stanford Medicine's unrivaled atmosphere of breakthrough thinking and interdisciplinary collaboration has fueled a long history of achievements.